A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis

by | Jun 8, 2026 | Clinical Trials | 0 comments

​ Conditions: Antiphospholipid Syndrome (APS); Thrombosis

Interventions: Biological: EA5; Biological: EA5

Sponsors: Shanghai Lanyi Therapeutics Co., Ltd.

Active, not recruiting Conditions: Antiphospholipid Syndrome (APS); Thrombosis
Interventions: Biological: EA5; Biological: EA5
Sponsors: Shanghai Lanyi Therapeutics Co., Ltd.
Active, not recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *